PinnyPeptide

AOD-9604 vs Tirzepatide

Side-by-side comparison: effects, dosing ranges, side effects, regulatory status, and reconstitution.

Peptide A

AOD-9604

Weight Management

Fat-metabolizing fragment of human growth hormone without growth-promoting effects.

Peptide B

Tirzepatide

Weight Management

Dual GIP/GLP-1 receptor agonist delivering unprecedented weight loss and metabolic benefits.

Typical vial

5 mg

Typical dose

250-500 mcg

Half-life

~30-60 minutes

FDA status

Not FDA approved as a drug. Granted GRAS status as a food ad…

Typical vial

5 mg

Typical dose

2500-15000 mcg

Half-life

~5 days (120 hours)

FDA status

FDA approved. Mounjaro (2022) for type 2 diabetes, Zepbound …

AOD-9604 effects

  • Stimulates lipolysis (fat breakdown) in adipose tissue
  • Inhibits lipogenesis (new fat formation)
  • Does not affect blood glucose or insulin levels
  • Does not elevate IGF-1 or bind the GH receptor
  • May support cartilage repair (emerging research)

Tirzepatide effects

  • Industry-leading weight loss (up to 22.5% body weight in trials)
  • Superior glycemic control with high rates of HbA1c normalization
  • Dual incretin receptor activation for complementary metabolic benefits
  • Significant reduction in waist circumference and visceral fat
  • Improved cardiometabolic risk factors (lipids, blood pressure)
  • Treatment of moderate-to-severe obstructive sleep apnea in obesity

AOD-9604 side effects

  • Injection site irritation or redness
  • Occasional headache
  • Mild nausea (uncommon)
  • Transient lightheadedness

Tirzepatide side effects

  • Nausea (most common, particularly during dose escalation)
  • Diarrhea
  • Decreased appetite
  • Vomiting
  • Injection site reactions

AOD-9604 dosing ranges

Fat loss and body composition

250-500 mcg · Once daily (SubQ) · 8-12 weeks

Tirzepatide dosing ranges

Type 2 diabetes (Mounjaro)

2500-15000 mcg · Once weekly (SubQ) · Ongoing as prescribed

Weight management (Zepbound)

2500-15000 mcg · Once weekly (SubQ, titrated over 20 weeks) · Ongoing as prescribed

Full AOD-9604 guide → Full Tirzepatide guide →

AOD-9604 vs Tirzepatide — common questions

What is the difference between AOD-9604 and Tirzepatide?

AOD-9604: Fat-metabolizing fragment of human growth hormone without growth-promoting effects. Typical dose 250-500 mcg. Tirzepatide: Dual GIP/GLP-1 receptor agonist delivering unprecedented weight loss and metabolic benefits. Typical dose 2500-15000 mcg. Both fall under the Weight Management category.

Can you stack AOD-9604 and Tirzepatide?

Stacking AOD-9604 with Tirzepatide is a protocol-design question best raised with a clinician — it depends on your goal, current bloodwork, and whether both peptides target overlapping mechanisms. Both peptides should be tracked independently with separate injection sites and timing. PinnyPeptide supports multi-peptide stacks with automatic injection site rotation.

Which is dosed more frequently, AOD-9604 or Tirzepatide?

AOD-9604 is typically dosed: Once daily (SubQ) for Fat loss and body composition. Tirzepatide is typically dosed: Once weekly (SubQ) for Type 2 diabetes (Mounjaro); Once weekly (SubQ, titrated over 20 weeks) for Weight management (Zepbound).

Are AOD-9604 and Tirzepatide FDA approved?

AOD-9604: Not FDA approved as a drug. Granted GRAS status as a food additive in 2014. Tirzepatide: FDA approved. Mounjaro (2022) for type 2 diabetes, Zepbound (2023) for chronic weight management, and (2024) for obstructive sleep apnea in adults with obesity.

Related peptide comparisons

aod-9604 vs cjc-1295aod-9604 vs ftpp-adipotideaod-9604 vs hgh-fragment-176-191aod-9604 vs ipamorelinaod-9604 vs retatrutideaod-9604 vs semaglutide

Tracking either of these?

Log doses, automate injection site rotation, and never lose track of where you last pinned. Free forever.

Get Started Free